Context Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Context Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-465,172	Closed	-$1.15M	–	532
2020 Q4	$1.15M	Hold	465,172	–	–	0.16%	127
2020 Q3	$1.47M	Sell	465,172 -235,000	-34%	-$751K	0.32%	79
2020 Q2	$2.04M	Buy	+700,172	New	+$2.21M	0.79%	35
2020 Q1	–	Sell	-713,782	Closed	-$2.32M	–	114
2019 Q4	$2.32M	Buy	+713,782	New	+$2.07M	1.16%	30

Other funds holding PDLI

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Public Employees Retirement Association of Colorado Denver, Colorado $28.9B AUM 44.1% 1-Year Est. Return

Context Capital Management's PDLI Position: Q1 2021 in Review

Context Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2021, closing a stake of 465,172 shares — an estimated $1.15M sold.

Context Capital Management first reported a position in PDLI in Q4 2019 and held it in 4 quarters. The position peaked at $2.32M in Q4 2019. 11 funds tracked by Wall St. Rank hold PDLI as of Q1 2021.

Context Capital Management reported no remaining PDL BioPharma, Inc. position as of Q1 2021 after selling out during the quarter.
Context Capital Management sold 465,172 PDL BioPharma, Inc. shares in Q1 2021, an estimated $1.15M.
Context Capital Management first reported a position in PDL BioPharma, Inc. in Q4 2019 and held it in 4 quarters.
Context Capital Management's PDL BioPharma, Inc. position peaked at $2.32M in Q4 2019.
11 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2021.

Based on Context Capital Management's 13F filing for Q1 2021, filed 17 May 2021.